Company intelligence / Profile preview

RythRx

Boston, Massachusetts, United States

Ownership: Private
Employees: ~283
Development stage: Other

Overview

IMCIVREE is approved and commercialized in multiple regions to treat hyperphagia and severe obesity caused by certain genetic defects affecting the MC4R pathway. Additional pipeline assets are in clinical or preclinical development targeting acquired hypothalamic obesity, congenital hyperinsulinism, and other related conditions. Peer-reviewed studies support efficacy of the lead asset.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RythRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RythRx.

Explore the full profile